Biocon Biologics recognized as Asia IP Elite for 2024 by IAM

Bengaluru: Biocon Biologics Limited, a subsidiary of Biocon Limited, has announced that it has once again been recognized as an Asia IP Elite for 2024 by IAM (Intellectual Asset Management), a Intellectual Property (IP) publication.

This is the eighth consecutive year for Biocon and subsequently its subsidiary Biocon Biologics to make it to this prestigious list. This prestigious accolade is awarded to a select group of Asia-based organisations that have demonstrated exceptional IP value creation and are considered leaders in the region.

In 2016, Biocon became the first and only Indian pharmaceutical company to be featured on the prestigious ASIA IP ELITE list for its IP management and consistent IP value creation. Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list.

Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said, “We are humbled to be recognized for the eighth consecutive year as an Asia IP Elite company by IAM, a testament to our commitment to innovation, intellectual property excellence, and patient-centric solutions. This accolade reinforces Biocon Biologics’ position as a leading global biosimilars company and underscores the critical role of our robust IP strategy in enabling affordable access to high quality biosimilar therapies worldwide. Our dedicated team continues to place IP at the core of our business, driving value creation and advancing healthcare solutions for millions of patients globally.”

Each year, the IAM editorial team conducts an extensive research process, incorporating both quantitative and qualitative analyses, to highlight an exclusive group of leading corporations and research institutions as inductees into the Asia IP Elite. Each member of the Asia IP Elite showcases excellence in IP value creation and meets the following criteria:

• Placing IP strategy at the centre of its business.

• Obtaining demonstrable, significant and ongoing value from intellectual property as a direct result of the strategies it employs.

• Possessing a senior management that understands the operational and strategic importance of intellectual property.

• Constantly reappraising and improving its IP strategy in order to take advantage of market developments. This year, 93 entities from India, China, Japan, South Korea, Malaysia, Thailand, Taiwan, Australia, New Zealand, and Singapore featured on the Asia IP Elite 2024 list.

Read also: USFDA approves Biocon Biologics Yesintek for Crohn's disease, Ulcerative Colitis, Plaque Psoriasis, Psoriatic Arthritis